A case of nevirapine-induced exfoliative dermatitis in an immunocompromised patient: a case report

Arvind Kumar; Dinesh Kansal; Usha K. Chaudhary; Ajay Sharma; Reena Sharma

doi:10.18203/2319-2003.ijbcp20150890

Authors

Arvind Kumar Department of Pharmacology, Dr. Rajendra Prasad Government Medical College, Tanda, Kangra, Himachal Pradesh
Dinesh Kansal Department of Pharmacology, Dr. Rajendra Prasad Government Medical College, Tanda, Kangra, Himachal Pradesh
Usha K. Chaudhary Department of Anaesthesia, Dr. Rajendra Prasad Government Medical College, Tanda, Kangra, Himachal Pradesh
Ajay Sharma Department of Cardiology, Dr. Rajendra Prasad Government Medical College, Tanda, Kangra, Himachal Pradesh
Reena Sharma Department of OBG, Dr. Rajendra Prasad Government Medical College, Tanda, Kangra, Himachal Pradesh

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150890

Keywords:

Highly active antiretroviral therapy, Human immunodeficiency virus, Exfoliative dermatitis, Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitor

Abstract

Nevirapine is a non-nucleoside reverse transcriptase inhibitor used as one of the first-line drugs for the highly active antiretroviral therapy (HAART) in human immunodeficiency virus positive patients. The side effects range from skin rashes to fulminant hepatotoxicity. The most of the side effects are manifested in the first 6-10 weeks indicating a need for close monitoring and follow-up of the patient in first few weeks. We hereby are presenting a case of a 41-year-old female who developed exfoliative dermatitis after 4 weeks of therapy.

Metrics

Metrics Loading ...

References

Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853-60.

Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton LB, Chabner B, Knollman B, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition. New York, NY: McGraw-Hill; 2011: 1642-3.

Patel SS, Benfield P. New drug profile: nevirapine. J Clin Immunother. 1996;6(4):307-17.

Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284(21):2722-3.

Safrin S. Antiviral agents. In: Katzung BG, Trevor AJ, editors. Basic and Clinical Pharmacology. 13th Edition. New York, McGraw-Hill; 2015: 850.

Ritter JM. A Textbook of Clinical Pharmacology and Therapeutics. Great Britain: Taylor & Francis; 2008: 62.

Sheran M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. HIV Clin Trials. 2005;6(3):158-68.

Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics. 2009;19(2):139-46.